Luteal Phase Support using Oral Dydrogesterone-a Prospective Treatment for Future Replacing Micronized Vaginal Progesterone

Kulvinder Kochar Kaur¹*, Gautam Allahbadia² and Mandeep Singh³

Received: September 03, 2018;   Published: September 10, 2018

DOI: 10.32474/OAJRSD.2018.01.000119

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Although micronized vaginal progesterone is the accepted norm for use in luteal phase support (LPS) in controlled ovarian stimulation (COS) that is used for in vitro fertilization (IVF) cycles, recently importance of oral Dydrogesterone has got the importance in lieu of its oral availability, cheap, no cumbersome side effects and no definitive newer fetal side effects. After the LOTUS 1 trial with a multicenter double placebo, double dummy design it has proved an equal efficacy if not superiority of oral D, over micronized vaginal progesterone and it seems D might soon become the standard of care for LPS in conventional IVF cycles besides its routine indication for recurrent abortions.

Keywords: LPS; COS; IVF; Dydrogesterone; Micronized vaginal progesterone

Abbreviations: LPS: Luteal Phase Support; COS: Controlled Ovarian Stimulation; IVF: In Vitro Fertilization; ET: Embryo Transfer

Abstract| Dydrogesterone(D)-Pharmacology| Advantages of an Oral preparation over other Routes| Problem of Vaginal administration for the Treating Physician| Safety of oral D| Fetal Safety| Cost Effectiveness of D| Conclusions| References|